The Oncology Program at NCH continues to strive to provide the best treatment and optimal care in Southwest Florida. Our Comprehensive Community Cancer Program is accredited by the Commission on Cancer (CoC), a quality program of the American College of Surgeons. Our accreditation demonstrates that we are committed to providing high-quality, multidisciplinary, patient-centered cancer care.

Required participation in the National Cancer Database (NCDB) and access to numerous quality reporting tools enable us to compare our provision and timeliness of care and improve performance based on nationally recognized quality measures and standards of cancer care.

The graphs below provide a comparison of NCH’s quality improvement measures to other approved cancer programs in Florida and also to all CoC accredited programs. NCH Healthcare System’s Cancer Program has exceeded all recognized standards of care and identifies accountability measures for those measures that are not standardized.
CP3R and NCH Healthcare System Performance for Breast

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CoC Standard= 90%)
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. (CoC Standard= 90%)

Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer.
Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CoC Standard=90%)

Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer. (CoC Standard= 80%)
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer.

**BCS**

<table>
<thead>
<tr>
<th></th>
<th>NCH</th>
<th>FL</th>
<th>All COC Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate (%)</td>
<td>83.5%</td>
<td>63.1%</td>
<td>66.2%</td>
</tr>
</tbody>
</table>

**CP3R Performance for Colon Cancer**

Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.

**ACT**

<table>
<thead>
<tr>
<th></th>
<th>NCH</th>
<th>FL</th>
<th>All COC Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate (%)</td>
<td>84.6%</td>
<td>80.3%</td>
<td>87.8%</td>
</tr>
</tbody>
</table>
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CoC Standard = 85%)

**CP3R Performance for Rectal Cancer**

Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer (CoC Standard= 85%)